Filtered By:
Source: Circulation
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 87 results found since Jan 2013.
Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial
Conclusions: In Chinese patients with negative cardiac troponin undergoing DES implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was mainly driven by a reduction in bleeding events without an increase in ischemic events.PMID:36335890 | DOI:10.1161/CIRCULATIONAHA.122.062762
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Hongyi Wu Lili Xu Xin Zhao Huanyi Zhang Kang Cheng Xiaoyan Wang Manhua Chen Guangping Li Jiangnan Huang Jun Lan Guanghe Wei Chi Zhang Yinman Wang Juying Qian Junbo Ge Source Type: research
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Conclusions: In critically-ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality.PMID:36036760 | DOI:10.1161/CIRCULATIONAHA.122.061533
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Erin A Bohula David D Berg Mathew S Lopes Jean M Connors Iljal Babar Christopher F Barnett Sunit-Preet Chaudhry Amit Chopra Wilson Ginete Michael H Ieong Jason N Katz Edy Y Kim Julia F Kuder Emilio Mazza Dalton McLean Jarrod M Mosier Ari Moskowitz Sabina Source Type: research
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients following acute MI.PMID:36030390 | DOI:10.1161/CIRCULATIONAHA.122.061612
Source: Circulation - August 28, 2022 Category: Cardiology Authors: Sunil V Rao Bodo Kirsch Deepak L Bhatt Andrzej Budaj Rosa Coppolecchia John Eikelboom Stefan K James W Schuyler Jones Bela Merkely Lars Keller Renicus S Hermanides Gianluca Campo Jos é Luis Ferreiro Taro Shibasaki Hardi Mundl John H Alexander Source Type: research
Ablation of Plasma Prekallikrein Decreases LDL Cholesterol by Stabilizing LDL Receptor and Protects against Atherosclerosis
Conclusions: PK regulates circulating cholesterol levels through binding to LDLR and inducing its lysosomal degradation. Ablation of PK stabilizes LDLR, decreases LDL cholesterol and prevents atherosclerotic plaque development. This study suggests that PK is a promising therapeutic target to treat ASCVD.PMID:35189703 | DOI:10.1161/CIRCULATIONAHA.121.056491
Source: Circulation - February 22, 2022 Category: Cardiology Authors: Jin-Kai Wang Yang Li Xiao-Lu Zhao Yuan-Bin Liu Jing Tan Yu-Ying Xing Dilare Adi Yong-Tao Wang Zhen-Yan Fu Yi-Tong Ma Song-Mei Liu Yong Liu Yan Wang Xiong-Jie Shi Xiao-Yi Lu Bao-Liang Song Jie Luo Source Type: research
Effect of Rivaroxaban and Aspirin in Patients with Peripheral Artery Disease Undergoing Surgical Revascularization: Insights from the VOYAGER PAD Trial
Conclusions: The efficacy of rivaroxaban is associated with a benefit in surgical LER patients. While bleeding was increased with rivaroxaban plus aspirin, the incidence was low, with no significant increase in fatal bleeding, intracranial hemorrhage or postprocedural bleeds requiring intervention. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02504216.PMID:34380322 | DOI:10.1161/CIRCULATIONAHA.121.054835
Source: Circulation - August 12, 2021 Category: Cardiology Authors: E Sebastian Debus Mark R Nehler Nicholas Govsyeyev Rupert M Bauersachs Sonia S Anand Manesh R Patel Fabrizio Fanelli Warren H Capell Taylor Brackin Franz Hinterreiter Dainis Krievins Patrice Nault Gabriele Piffaretti Alexei Svetlikov Nicole Jaeger Connie Source Type: research
Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association
Circulation. 2021 Jul 28:CIR0000000000001005. doi: 10.1161/CIR.0000000000001005. Online ahead of print.ABSTRACTLower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation). Despite its prevalence and clinical importance, PAD has been historically underappreciated by health care professionals and patients. This underappreciation seems multifactorial (eg, limited availability of the first-line diagnostic test, the a...
Source: Circulation - July 28, 2021 Category: Cardiology Authors: Michael H Criqui Kunihiro Matsushita Victor Aboyans Connie N Hess Caitlin W Hicks Tak W Kwan Mary M McDermott Sanjay Misra Francisco Ujueta American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vasc Source Type: research
Perioperative Neurological Evaluation and Management to Lower the Risk of Acute Stroke in Patients Undergoing Noncardiac, Nonneurological Surgery: A Scientific Statement From the American Heart Association/American Stroke Association
Circulation. 2021 Apr 8:CIR0000000000000968. doi: 10.1161/CIR.0000000000000968. Online ahead of print.ABSTRACTPerioperative stroke is a potentially devastating complication in patients undergoing noncardiac, nonneurological surgery. This scientific statement summarizes established risk factors for perioperative stroke, preoperative and intraoperative strategies to mitigate the risk of stroke, suggestions for postoperative assessments, and treatment approaches for minimizing permanent neurological dysfunction in patients who experience a perioperative stroke. The first section focuses on preoperative optimization, including...
Source: Circulation - April 8, 2021 Category: Cardiology Authors: Curtis Benesch Laurent G Glance Colin P Derdeyn Lee A Fleisher Robert G Holloway Steven R Mess é Christina Mijalski M Timothy Nelson Martha Power Babu G Welch American Heart Association Stroke Council; Council on Arteriosclerosis, Thrombosis and Vascular Source Type: research
Primary Outcome Evaluation of a Next Generation Left Atrial Appendage Closure Device: Results from the PINNACLE FLX Trial
Conclusions: LAA closure with this next generation LAA closure device was associated with a low incidence of adverse events and a high incidence of anatomic closure. Clinical Trial Registration: URL https://clinicaltrials.gov Unique Identifier NCT02702271.PMID:33820423 | DOI:10.1161/CIRCULATIONAHA.120.050117
Source: Circulation - April 6, 2021 Category: Cardiology Authors: Saibal Kar Shephal K Doshi Ashish Sadhu Rodney Horton Jose Osorio Christopher Ellis James Stone Manish Shah Srinivas R Dukkipati Stuart Adler Devi G Nair Jamie Kim Oussama Wazni Matthew J Price Federico M Asch David R Holmes Robert D Shipley Nicole T Gord Source Type: research
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: Despite many differences in baseline characteristics between women and men and higher baseline endogenous factor Xa levels in women, the intensity of anticoagulation achieved with edoxaban between the sexes was similar. Treatment with higher-dose edoxaban regimen resulted in an even greater reduction in hemorrhagic stroke and several serious bleeding outcomes in women than in men, whereas the efficacy profile was similar between sexes.
PMID: 33587659 [PubMed - as supplied by publisher]
Source: Circulation - February 16, 2021 Category: Cardiology Authors: Zelniker TA, Ardissino M, Andreotti F, O'Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA Tags: Circulation Source Type: research
